Posts tagged “Quintiles”
Quintiles' new service package; Intel's buy; Samsung exec stays; BlackBerry's encryption deal; EU pressures Google
In today's Bulldog wrapup of life science and technology news: Quintiles bundles a series of services for drug firms; Intel buys PasswordBox; Samsung keeps mobile business chief; BlackBerry signs encryption deal with Germany; and the EU steps up pressure on Google.
A new report says 895 clinical trials for new drugs targeting a wide variety of diseases are underway in North Carolina. But the "Research in Your Backyard" report says greater diversity in races, ages, sex and sexual orientation are needed.
Quintiles, Metabolon CEOs headline CED biotech conference; diversity in emojis?; AT&T hiring in Triangle; AT&T's big buy; YouTube amends copyright
In today's Bulldog wrapup of technology and life science news: The CEO of Quintiles along with the CEO of Metabolon headline the CED's biotech conference; Those emojis you like to use may soon come in colors; AT&T is hiring in Raleigh; AT&T making a big buy in Mexico; and YouTube amends copyright form.
Founder Dennis Gillings and other key investors are selling 13 million shares in Quintiles, and the world's largest life science services firm is buying $250 million of them through an underwriter. The deal means Quintiles' big investors now own less than 50 percent of the company and some changes in governance are coming as a result, a spokesperson says.
Quintiles CEO Tom Pike is on the lookout for more acquisitions. In a quarterly earnings conference call Thursday, Pike said the world's largest life science services company is on the "lookout" to put acquisition targets "under our wing." Our Insider subscribers get the details.
In the midst of the deadly Ebola outbreak and the rushing to trial of experimental treatments, the world's top life sciences services company is calling for faster drug and vaccine development. In a 21st Century Cures Initiative discussion hosted by Rep. Renee Ellmers on Thursday, the head of the Phase 1 Clinical Research Division at Quintiles, said Phase 1 trial "timelines" should be reduced by "addressing inefficiencies and redundancies." Quintiles has helped develop and commercialize all of the world's top 100 selling drugs in 2013.
Tom Pike, CEO of Quintiles, sees a new wave of business coming for life science services companies. And the world's largest contract research organization is ready to capitalize on "risk-based monitoring," he says in a conference call.
Quintiles, the world's largest life science company, says new business surged 21 percent in its most recent quarter, driving revenues to $1.035 billion compared to $944 million a year ago. Earnings jumped 30 percent to 65 cents per share. Quintiles also adjusted upward its financial expectations for the year.
In today's Bulldog wrapup of technology and life science news: Pozen resubmits a drug application; Amazon to fight FTC over kid apps purchases; Furiex and Quintiles deals close; Twitter names a new CFO
Contract research organizations aren't what they used to be. But, they are where they used to be: in North Carolina.
Quintiles CEO Tom Pike says Quintiles' ability to offer pharmas more than simply outsourced clinical trial services will lead to the company's growth. Read more about his comments to analysts and investors at Goldman Sach's healthcare conference.
Quintiles, the world's largest life science services company, is adding another honor. After being named to the Fortune 500 earlier this week, Quintiles on Friday was selected for the CIO 100 list for information technology innovation.
Quintiles CEO Tom Pike has said in the past that the world's largest life science services company would keep making acquisitions after going public a year ago. True to his word, Pike is growing Quintiles again in a deal for Houston-based Encore. How does the deal boost the big "Q"? By the way, don't expect any jobs to move to N.C. WRAL TechWire Insiders find out.
Quintiles, the world's largest provider of life science industry services, is growing a bit bigger but adding more expertise in healthcare analytics through the acquisition of Encore Health Resources.
From our archives: The Fred Eshelman saga includes one-person startup at PPD to Wilmington's Walk of Fame and now a $1.1B sale of Furiex
Looking back at Fred Eshelman's career: A 2009 blog post recapped a tumultuous year for Eshelman and PPD in which the company's stock was hammered and he stepped down as CEO to become executive chairman. But the year was capped with a salute. From there, Eshelman has continued to make headlines.